Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Differentiating the efficacy of 5-HT(1B/1D) agonists.

F D Sheftell1, A W Fox, R E Weeks

  • 1New England Center for Headache, Stamford, CT 06902, USA.

Headache
|March 27, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Behavioral factors in the placebo response.

Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology·2011
Same author

Case of Indurated Mediastino-Pericarditis.

British medical journal·2010
Same author

Cirrhosis in a Boy Aged Eleven Years: Jaundice of Nearly Three Years' Duration.

British medical journal·2010
Same author

Case of Progressive Muscular Atrophy, with Bulbar Paralysis.

British medical journal·2010
Same author

Link between confusional migraine, hemiplegic migraine and episodic ataxia type 2: hypothesis, family genealogy, gene typing and classification.

Cephalalgia : an international journal of headache·2009
Same author

Key points in migraine prophylaxis: patient perspective.

Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology·2009

Transforming migraine drug efficacy data into therapeutic gain (TG) or number needed to treat (NNT) does not add new information. These measures should not be used for comparing serotonin (5-HT(1B/1D)) agonists; head-to-head studies are necessary.

Area of Science:

  • Clinical pharmacology
  • Migraine treatment research
  • Biostatistics in clinical trials

Background:

  • Published clinical trials for serotonin (5-HT(1B/1D)) agonists in migraine treatment commonly use pain score changes as a primary endpoint.
  • Placebo response rates in these trials can be variable.
  • Meta-analyses frequently utilize therapeutic gain (TG) and number needed to treat (NNT) to compare drug efficacy.

Purpose of the Study:

  • To evaluate the utility of transforming efficacy data into therapeutic gain (TG) and number needed to treat (NNT) for published clinical trials of serotonin (5-HT(1B/1D)) agonists used in acute migraine treatment.
  • To determine if these transformed metrics offer additional insights beyond standard efficacy measures.

Main Methods:

  • Efficacy data from US product labeling and published sources were converted into TG (active response rate minus placebo response rate) and NNT (1/TG).

Related Experiment Videos

  • Pivotal clinical trial data were analyzed before and after this transformation.
  • Relationships between TG, NNT, clinical disability, and placebo response rates were examined using correlation coefficients.

    • Main Results:

    • Therapeutic gain (TG) values ranged from 17.5% to 51% across the analyzed trials.
    • For a significant portion of trials (17.5% to 47%), transforming TG into NNT did not reveal clinically significant differences in efficacy estimates.
    • TG showed a stronger correlation with clinical disability (R = 0.93) than NNT, while NNT correlated more strongly with placebo response rates (R = 0.66) than TG did.

    Conclusions:

    • The transformation of efficacy rates into TG or NNT provides no novel information for placebo-controlled migraine trials.
    • TG and NNT are not suitable metrics for comparing different drugs within the serotonin (5-HT(1B/1D)) agonist class.
    • Accurate comparison of migraine therapies necessitates well-designed head-to-head studies, not meta-analyses relying on TG or NNT.
    • Broader efficacy measures are recommended for describing and comparing the effectiveness of 5-HT(1B/1D) agonists.